These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 31874110)

  • 41. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
    Meeusen B; Cortesi EE; Domènech Omella J; Sablina A; Ventura JJ; Janssens V
    Cancer Lett; 2021 Nov; 520():57-67. PubMed ID: 34216687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis.
    Zeng B; Ge C; Li R; Zhang Z; Fu Q; Li Z; Lin Z; Liu L; Xue Y; Xu Y; He J; Guo H; Li C; Huang W; Song X; Huang Y
    Biomed Pharmacother; 2020 Jan; 121():109562. PubMed ID: 31707341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
    Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
    Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.
    Wang HH; Fan SQ; Zhan YT; Peng SP; Wang WY
    Int J Biol Macromol; 2024 Jan; 254(Pt 3):127976. PubMed ID: 37951442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression.
    Eichelmann AK; Mayne GC; Chiam K; Due SL; Bastian I; Butz F; Wang T; Sykes PJ; Clemons NJ; Liu DS; Michael MZ; Karapetis CS; Hummel R; Watson DI; Hussey DJ
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074015
    [No Abstract]   [Full Text] [Related]  

  • 47. The splicing factor SF3B1 confers ferroptosis resistance and promotes lung adenocarcinoma progression via upregulation of SLC7A11.
    Guo Y; Wang X; Du Y; Zhao Y; Gao L; Hao Y; Lv D; Feng X; Zhai Y; Zou B; Han J; Xu E; Yang Y; Yang B; Xi Y; Zhang L
    Cancer Gene Ther; 2024 Oct; 31(10):1498-1510. PubMed ID: 39127833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
    J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
    Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
    Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
    Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of
    Kim S; Kim J; Jung Y; Jun Y; Jung Y; Lee HY; Keum J; Park BJ; Lee J; Kim J; Lee S; Kim J
    Mol Cells; 2020 Jul; 43(7):619-631. PubMed ID: 32638704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
    Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
    Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The m
    Ma L; Chen T; Zhang X; Miao Y; Tian X; Yu K; Xu X; Niu Y; Guo S; Zhang C; Qiu S; Qiao Y; Fang W; Du L; Yu Y; Wang J
    Redox Biol; 2021 Jan; 38():101801. PubMed ID: 33232910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
    Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
    Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
    Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
    Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergy of WEE1 and mTOR Inhibition in Mutant
    Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
    Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
    [No Abstract]   [Full Text] [Related]  

  • 60. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
    Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
    Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.